A new wave of metabolic disease drugs beyond GLP-1 agonists is emerging to address the unmet needs of patients.

Discover the emergence of dual-payload ADCs and PDCs, which could mark a significant evolution in targeted therapeutics.

Lonza helps biotech firms accelerate from DNA to IND with tailored strategies that reduce risk and speed complex biologics to ...

Discover six obesity deals made so far in 2025, with dealmaking activity in the field being largely dominated by big pharma companies.

While non-exhaustive, this list offers an overview of the year’s biotech events taking place around the world, aimed at partnering and connecting with decision makers in biopharma. If there is a ...

Developing treatments for neurological diseases presents a huge challenge for neuroscience companies within the biotech industry. The central nervous system (CNS) is extremely complex, and many ...

Once a booming field, bustling with innovation and money driving that innovation, the cell and gene therapy sector is now struggling to fuel therapeutic growth to bring medicines to patients. It doesn ...

Asking whether China is the future of the biotech industry might seem counterintuitive, considering the current biotech geopolitical context. If you haven’t followed this series of events, a ...

Last year, we took a look at the biotech trends that we thought would shape 2024. Now, as we enter the new year, the biotech industry is continuing to evolve at a rapid pace, and 2025 is shaping up to ...

Aiolos Bio has emerged as a significant player in the biopharmaceutical industry, with a focus on developing treatments for respiratory and inflammatory diseases. The company’s launch in 2023, backed ...